Skip to main content
. 2014 Sep 24;16(5):434. doi: 10.1186/s13075-014-0434-z

Figure 3.

Figure 3

Plasma CXCL13 at 0 and 6 months, in patients with high- and low-level CXCL13 in the treatment groups. Plasma levels of CXCL13 at 0 and 6 months in the DMARD group, the DMARD + ADA group and all patients, subdivided into ‘CXCL13-high’ and ‘CXCL13-low’ according to baseline level of CXCL13 ≥100 vs. <100. ***Indicates P <0.001, **: P <0.01, and ns: P >0.05. ADA: adalimumab; CXCR13: C-X-C chemokine receptor type 13; DMARD: disease-modifying anti-rheumatic drug.